What are the guidelines for taking Xarelto (Rivaroxaban) before surgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 1, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Xarelto (rivaroxaban) should be stopped at least 1 day before low-to-moderate-bleed-risk surgery and 2 days before high-bleed-risk surgery, as recommended by the most recent guidelines 1.

Perioperative Management of Xarelto

When considering the management of Xarelto before surgery, it's crucial to balance the risk of bleeding against the risk of thromboembolic events. The decision on when to stop Xarelto should be individualized based on the patient's renal function, the type of surgery, and the associated bleeding risk.

  • For patients undergoing low-to-moderate-bleed-risk procedures, stopping Xarelto 1 day before surgery is generally recommended 1.
  • For those undergoing high-bleed-risk procedures, a longer period of 2 days off Xarelto before surgery is advised 1.

Considerations for Renal Function

Patients with renal impairment may require earlier cessation of Xarelto due to the drug's pharmacokinetics and the potential for accumulation. However, specific guidance on adjusting the timing based on renal function is not provided in the most recent guideline 1, suggesting that the primary consideration should be the bleed risk associated with the surgery.

Resumption of Xarelto Post-Surgery

After surgery, Xarelto can typically be resumed once adequate hemostasis is achieved, usually within 24-48 hours 1. The exact timing may depend on the surgical procedure and the patient's individual risk factors. In some cases, bridging therapy with shorter-acting anticoagulants may be necessary, particularly for patients at high risk of thromboembolic events.

Clinical Decision Making

The management of Xarelto in the perioperative period should be guided by the most recent clinical practice guidelines, taking into account the patient's specific clinical context, including renal function, type of surgery, and individual risk factors for bleeding and thrombosis 1.

From the FDA Drug Label

If anticoagulation must be discontinued to reduce the risk of bleeding with surgical or other procedures, XARELTO should be stopped at least 24 hours before the procedure to reduce the risk of bleeding [see Warnings and Precautions (5. 2)] . In deciding whether a procedure should be delayed until 24 hours after the last dose of XARELTO, the increased risk of bleeding should be weighed against the urgency of intervention XARELTO should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established, noting that the time to onset of therapeutic effect is short [see Warnings and Precautions (5.1)] .

XARELTO Administration Before Surgery:

  • XARELTO should be stopped at least 24 hours before the procedure to reduce the risk of bleeding.
  • The decision to delay a procedure should weigh the increased risk of bleeding against the urgency of intervention.
  • XARELTO can be restarted after the procedure as soon as adequate hemostasis has been established 2.

From the Research

Perioperative Management of Xarelto (Rivaroxaban) Before Surgery

  • The management of direct oral anticoagulants (DOACs) like rivaroxaban in patients undergoing surgery is crucial to decrease the risks of bleeding and thromboembolism 3.
  • For elective surgical or nonsurgical procedures, a standardized approach to perioperative DOAC management involves classifying the risk of procedure-related bleeding as minimal, low to moderate, or high risk 3.
  • Patients undergoing minimal bleeding risk procedures may continue DOACs, while those undergoing low to moderate bleeding risk procedures should typically discontinue DOACs 1 day before the operation and restart DOACs 1 day after 3.
  • Patients undergoing high bleeding risk procedures should stop DOACs 2 days prior to the operation and restart DOACs 2 days after 3.

Efficacy and Safety of Rivaroxaban in Preventing VTE

  • Rivaroxaban has been shown to be effective in preventing venous thromboembolism (VTE) in patients undergoing major orthopedic surgery, with comparable safety to enoxaparin 4.
  • A network meta-analysis found that DOACs, including rivaroxaban, are safe and efficacious alternatives to low-molecular-weight heparins (LMWHs) for VTE prophylaxis in cancer patients undergoing surgery 5.
  • A randomized blinded non-inferiority study found that rivaroxaban is non-inferior to enoxaparin in terms of VTE prophylaxis in degenerative spine surgeries, with shorter hospital stays and lower reoperation rates in the rivaroxaban group 6.

Management of Anticoagulation with Rivaroxaban in Trauma and Acute Care Surgery

  • A study found that rivaroxaban patients had fewer surgical or interventional radiology procedures during admission, and less frequently underwent anticoagulant reversal, compared to warfarin patients 7.
  • The study also found that bleeding complications, VTE complications, and mortality were not significantly different between rivaroxaban and warfarin patients 7.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

6
Research

Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2025

Related Questions

What is the next management step for a 75-year-old male on Direct Oral Anticoagulant (DOAC) for atrial fibrillation (a fib) with recurrent epistaxis and stable vital signs, but ongoing bleeding from the right nostril?
What is the most appropriate management for an elderly patient with atrial fibrillation and coronary artery disease, taking a direct oral anticoagulant (DOAC), presenting with recurrent nose bleeds?
How long should anticoagulant therapy be continued after surgery?
What are the guidelines for managing anticoagulant medications, such as warfarin (International Normalized Ratio (INR)) and direct oral anticoagulants (DOACs) like rivaroxaban (Xarelto), apixaban (Eliquis), or dabigatran (Pradaxa), before and after surgery?
What is the recommended anticoagulant and anti-platelet therapy for a patient with persistent Atrial Fibrillation (AFib) and a history of Barrett's esophagus, 4 weeks post-surgery with an atrial clip, taking pantoprazole?
At what level should an esophageal (food pipe) probe be positioned?
Is Anastrozole (generic name) safe to use preoperatively?
What are the considerations for surgery in patients taking Losartan (angiotensin II receptor antagonist)?
Why does the bioavailability of Gabapentin (Gabapentin) decrease with increasing doses?
Is it acceptable to initiate 0.4 milligrams of tamsulosin in a 90-year-old patient with nocturia without prior Prostate-Specific Antigen (PSA) confirmation?
What is Benign Prostatic Hyperplasia (BPH)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question